PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Seelos Therapeutics, Inc. (SEEL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US81577F1093

CUSIP

81577F109

Sector

Healthcare

IPO Date

Apr 19, 1999

Highlights

Market Cap

$214.97K

EPS (TTM)

$351.04

PE Ratio

0.00

Total Revenue (TTM)

$1.61M

Gross Profit (TTM)

$1.56M

EBITDA (TTM)

-$17.16M

Year Range

$0.37 - $247.04

Target Price

$120.00

Short %

29.52%

Short Ratio

0.14

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
SEEL vs. CMPS SEEL vs. GHRS SEEL vs. PFE
Popular comparisons:
SEEL vs. CMPS SEEL vs. GHRS SEEL vs. PFE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Seelos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovember
-100.00%
7.68%
SEEL (Seelos Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period


SEEL

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of SEEL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-26.62%26.47%-54.19%-52.79%-46.24%-50.25%-36.35%-23.21%-19.57%-72.84%-99.78%
202319.60%-2.72%-12.51%-0.16%34.95%28.32%28.03%-28.76%-83.12%0.92%-77.38%10.32%-93.18%
2022-30.06%-7.02%-20.96%-26.00%4.60%4.90%23.50%34.49%-8.85%-15.59%-5.84%-17.05%-58.34%
202136.71%37.50%68.01%22.04%-49.43%-14.29%-14.77%-2.22%9.55%-10.37%-19.91%-5.78%3.16%
2020-22.39%-15.67%-44.07%44.75%73.24%-17.89%14.85%-21.53%2.94%-21.02%32.43%61.22%17.91%
2019-21.88%-58.89%81.62%-10.42%-20.60%-8.37%-20.09%-22.86%-32.00%-1.91%-4.49%55.80%-76.74%
201824.46%-59.83%-55.85%-33.59%3.82%39.29%-23.08%10.00%-6.03%9.32%-9.73%-37.25%-89.57%
201786.92%19.34%-27.24%-46.45%-19.17%23.71%21.24%18.98%4.91%-2.34%-5.39%16.46%41.54%
20160.00%0.00%-33.07%-8.16%-18.48%-8.16%-22.78%13.71%-3.56%-40.59%-29.35%-8.45%-85.02%
20150.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
20140.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
20130.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of SEEL is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of SEEL is 88
Overall Rank
The Sharpe Ratio Rank of SEEL is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of SEEL is 00
Sortino Ratio Rank
The Omega Ratio Rank of SEEL is 11
Omega Ratio Rank
The Calmar Ratio Rank of SEEL is 00
Calmar Ratio Rank
The Martin Ratio Rank of SEEL is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Seelos Therapeutics, Inc. (SEEL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
SEEL
^GSPC

There is not enough data available to calculate the Sharpe ratio for Seelos Therapeutics, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovember
-0.55
2.51
SEEL (Seelos Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Seelos Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovember
-100.00%
-1.80%
SEEL (Seelos Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Seelos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Seelos Therapeutics, Inc. was 100.00%, occurring on Nov 18, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Mar 28, 20162178Nov 18, 2024
-15.5%Dec 12, 20082Dec 15, 20082Dec 17, 20084
-6.71%Jan 13, 20162Jan 14, 20161Jan 15, 20163
-2.08%Dec 14, 20151Dec 14, 20152Dec 16, 20153

Volatility

Volatility Chart

The current Seelos Therapeutics, Inc. volatility is 60.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%JulyAugustSeptemberOctoberNovember
60.16%
4.06%
SEEL (Seelos Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Seelos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Seelos Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab